Enanta Pharmaceuticals Inc share price logo

Enanta Pharmaceuticals Inc Share Price

NASDAQ: ENTA

Small Cap

$14.61

+0.52

(+3.69%)

as on

Enanta Pharmaceuticals Inc Stock Performance

as on December 6, 2025 at 2:29 am IST

  • Day's Low

    Day's High

    $13.89
    $14.65
    downward going graph

    4.93%

    Downside

    0.27%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $4.09
    $15.34
    downward going graph

    72.01%

    Downside

    5.00%

    Upside

    downward going graph

Enanta Pharmaceuticals Inc share price movements today

Previous Close
$14.09
Open
$14.25
Volume
379.4K
Day's Low - High
$13.89 - $14.65
52 Week Low - High
$4.09 - $15.34

Enanta Pharmaceuticals Inc Historical Returns

1 Month Return
+ 29.76 %
3 Month Return
+ 60.11 %
1 Year Return
+ 76.9 %
3 Year Return
-67.09 %
5 Year Return
-66.79 %

Enanta Pharmaceuticals Inc Stock Fundamentals & Key Indicators

Check Enanta Pharmaceuticals Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$410.9M

EPS (TTM)

-3.7471

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-0.66%

PE Ratio (TTM)

-2.39

Industry PE ratio

-0.4116938110749186

PEG Ratio

0

EBITDA

-80.8M

Revenue (TTM)

65.3M

Profit Margin

-125.36%

Return On Equity TTM

-84.63%

Enanta Pharmaceuticals Inc Stock Valuation

Track how Enanta Pharmaceuticals Inc P/E has moved over time to understand its valuation trends.

Enanta Pharmaceuticals Inc in the last 5 years

  • Overview

  • Trends

Lowest (-15.76x)

December 31, 2021

Today (-2.39x)

December 5, 2025

Industry (-0.41x)

December 5, 2025

Highest (-1.36x)

March 31, 2025

LowHigh

Today’s Price to Earnings Ratio: -2.39x

Enanta Pharmaceuticals Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Enanta Pharmaceuticals Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
BUY$410.9M-66.79%-2.39-125.36%
BUY$43.7B410.81%-16.34-264.83%
BUY$62.5B258.57%1690.321.36%
BUY$118.7B100.27%30.4931.35%
BUY$76.7B46.78%17.3332.13%

Stock Returns calculator for Enanta Pharmaceuticals Inc Stock including INR - Dollar returns

The Enanta Pharmaceuticals Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Enanta Pharmaceuticals Inc investment value today

Current value as on today

₹1,88,554

Returns

₹88,554

(+88.55%)

Returns from Enanta Pharmaceuticals Inc Stock

₹82,397 (+82.4%)

Dollar Returns*

₹6,157 (+6.16%)

Analyst Recommendation on Enanta Pharmaceuticals Inc Stock

Based on 14 analysts

BUY

64.29%

Buy

28.57%

Hold

7.14%

Sell

Based on 14 analysts, 64.29% of analysts recommend a 'BUY' rating for Enanta Pharmaceuticals Inc. Average target price of $19.12

Enanta Pharmaceuticals Inc Share Price Target

Get share price movements and forecasts by analysts on Enanta Pharmaceuticals Inc.

What analysts predicted

23.59%UPSIDE

Target Price

$19.12

Current Price

$14.61

Analyzed by

14 Analysts

Target

$19.12

Enanta Pharmaceuticals Inc target price $19.12, a slight upside of 23.59% compared to current price of $14.61. According to 14 analysts rating.

Enanta Pharmaceuticals Inc Stock’s Investor Sentiment and Interest

Search interest for Enanta Pharmaceuticals Inc Stock has increased by 67% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:67% versus previous 30 day period

Enanta Pharmaceuticals Inc Quarterly Profit & Loss

All numbers in Millions USD

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Total Revenue
18
18
18
17
17
14
16
14
18
15
Gross Profit
18
18
18
17
17
14
16
14
18
15
Operating Income
-36
-31
-34
-32
-24
-29
-23
-24
-18
-18
EBITDA
-32
-25
-29
-28
-20
-26
-19
-21
-15
-16
Interest Expense
1
3
3
2
2
2
1
1
1
2
Depreciation
0
0
0
0
0
0
0
1
1
1
Income Before Tax
-34
-29
-34
-31
-23
-29
-22
-23
-18
-18
Income Tax Expense
4
-1
0
0
0
0
0
-1
0
0
Net Income
-39
-28
-33
-31
-22
-28
-22
-22
-18
-18
Net Profit Margin
-206.78%
-148.46%
-185.56%
-182.70%
-126.08%
-197.32%
-131.43%
-151.71%
-99.68%
-123.64%

Enanta Pharmaceuticals Inc Annual Profit & Loss

All numbers in Millions USD

Sep 2016
Sep 2017
Sep 2018
Sep 2019
Sep 2020
Sep 2021
Sep 2022
Sep 2023
Sep 2024
Sep 2025
Total Revenue
88
102
206
205
122
97
86
79
67
65
Gross Profit
88
102
206
205
122
97
86
79
67
65
Operating Income
30
24
88
36
-41
-109
-123
-137
-121
-85
EBITDA
32
26
90
39
-37
-106
-119
-123
-104
-70
Interest Expense
0
0
4
8
10
5
1
5
10
7
Depreciation
-
2
2
3
3
3
2
2
2
4
Income Before Tax
32
26
93
45
-35
-107
-122
-130
-117
-83
Income Tax Expense
10
9
21
0
1
-28
0
2
-1
-1
Net Income
21
17
71
46
-36
-78
-121
-133
-116
-81
Net Profit Margin
24.55%
17.23%
34.82%
22.60%
-29.53%
-81.38%
-141.31%
-168.95%
-171.58%
-125.36%

Enanta Pharmaceuticals Inc Quarterly Cash Flow

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Net Income
-28
-33
-31
-22
-28
-22
-22
-18
-18
Operating Cash Flow
-21
-24
-28
-14
-10
-16
-13
17
-6
Investing Cash Flow
11
-13
58
-6
19
68
-4
-26
-
Financing Cash Flow
0
-7
-6
-6
-7
-4
-6
-6
-8
Change in Cash
-9
-45
23
-27
1
47
-24
-15
-12

Enanta Pharmaceuticals Inc Annual Cash Flow

All numbers in Millions USD

Sep 2017
Sep 2018
Sep 2019
Sep 2020
Sep 2021
Sep 2022
Sep 2023
Sep 2024
Sep 2025
Net Income
17
71
46
-36
-78
-121
-133
-116
-81
Operating Cash Flow
52
29
71
7
-69
-84
-103
-78
-19
Investing Cash Flow
-4
-35
-86
19
36
54
-53
58
40
Financing Cash Flow
1
4
2
8
3
20
198
-27
-26
Change in Cash
49
-1
-12
35
-29
-9
41
-48
-5

Global Institutional Holdings in Enanta Pharmaceuticals Inc

Funds
Holdings
Farallon Capital Management, L.L.C.
9.93%
Krensavage Asset Management, LLC
9.89%
Vanguard Group Inc
9.25%
BlackRock Inc
8.64%
Millennium Management LLC
6.82%

Enanta Pharmaceuticals Inc News & Key Events

  • img

    Today's Timeline - 29 November

    Sun, 05:52 AM

    -

    Enanta Pharmaceuticals' common stock and options are under a Lock-Up Agreement ending on November 30, 2025.

Insights on Enanta Pharmaceuticals Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, ENTA stock has moved up by 29.8%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Insmed Incorporated has given 172.2% return, outperforming this stock by 95.3%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Insmed Incorporated has given 930.9% return, outperforming this stock by 998.0%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 18.31M → 15.12M (in $), with an average decrease of 17.4% per quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, -18.25M → -18.7M (in $), with an average decrease of 2.4% per quarter

About Enanta Pharmaceuticals Inc

enanta pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. enanta is discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis c virus (hcv). these inhibitors include members of the direct acting antiviral (daa) inhibitor classes – protease (partnered with abbvie), ns5a, and nucleotide polymerase – as well as a host-targeted antiviral (hta) inhibitor class targeted against cyclophilin. enanta’s lead protease inhibitor, paritaprevir, is part of abbvie’s recently approved hcv treatment regimen. in addition, enanta has a preclinical program in non-alcoholic steatohepatitis, or nash, which is a condition that results in liver inflammation and damage caused by a buildup of fat in the liver. enanta pharmaceuticals is a public company with offices in watertown, ma.
OrganisationEnanta Pharmaceuticals Inc
Headquarters4 Kingsbury Avenue, Watertown, MA, United States, 02472
IndustryHealth Technology
CEODr. Jay R. Luly Ph.D.
E-voting on sharesClick here to vote

Key Management of Enanta Pharmaceuticals Inc

Name

Title

Ms. Jennifer Viera

Executive Director of Investor Relations & Corporate Communications

Mr. Nathaniel S. Gardiner J.D.

Consultant

Ms. Tara Lynn Kieffer Ph.D.

Chief Product Strategy Officer

Dr. Jay R. Luly Ph.D.

President, CEO & Director

Dr. Yat Sun Or Ph.D.

Chief Scientific Officer

Mr. Matthew P. Kowalsky J.D.

Chief Legal Officer & Corporate Secretary

Mr. Harry R. Trout III

Interim Principal Financial Officer

Ms. Kathleen S. Capps CPA

Interim Principal Accounting Officer

Mr. Brendan Luu

Chief Business Officer

Dr. Scott T. Rottinghaus M.D.

Chief Medical Officer

FAQs

What is Enanta Pharmaceuticals Inc share price today?

Enanta Pharmaceuticals Inc share price today is $14.61 as on at the close of the market. Enanta Pharmaceuticals Inc share today touched a day high of $14.65 and a low of $13.89.

What is the 52 week high and 52 week low for Enanta Pharmaceuticals Inc share?

Enanta Pharmaceuticals Inc share touched a 52 week high of $15.34 on and a 52 week low of $4.09 on . Enanta Pharmaceuticals Inc stock price today i.e. is closed at $14.61,which is 4.76% down from its 52 week high and 257.21% up from its 52 week low.

What is Enanta Pharmaceuticals Inc's market capitalisation today?

Enanta Pharmaceuticals Inc market capitalisation is $0.00T as on .

How to invest in Enanta Pharmaceuticals Inc Stock (ENTA) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Enanta Pharmaceuticals Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Enanta Pharmaceuticals Inc Shares that will get you 0.1027 shares as per Enanta Pharmaceuticals Inc share price of $14.61 per share as on December 6, 2025 at 2:29 am IST.

What is the minimum amount required to buy Enanta Pharmaceuticals Inc Stock (ENTA) from India?

Indian investors can start investing in Enanta Pharmaceuticals Inc (ENTA) shares with as little as ₹89.927 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹899.27 in Enanta Pharmaceuticals Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Enanta Pharmaceuticals Inc share’s latest price of $14.61 as on December 6, 2025 at 2:29 am IST, you will get 0.6845 shares of Enanta Pharmaceuticals Inc. Learn more about fractional shares .

What are the returns that Enanta Pharmaceuticals Inc has given to Indian investors in the last 5 years?

Enanta Pharmaceuticals Inc stock has given -66.79% share price returns and 21.87% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?